Cargando…

Comprehensive characterization of HER2-low breast cancers: implications in prognosis and treatment

BACKGROUND: HER2-low cancers are heterogeneous with different degrees of HER2 expression and hormone receptor (HR) status. Currently, its analysis is mostly focused on the standard clinic-pathologic features or common biomarkers expression, without considering the heterogeneity within the category....

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yuyang, Tsang, Julia Y., Tam, Fiona, Loong, Thomson, Tse, Gary M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130469/ https://www.ncbi.nlm.nih.gov/pubmed/37068349 http://dx.doi.org/10.1016/j.ebiom.2023.104571

Ejemplares similares

Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
por: Tarantino, P., et al.
Publicado: (2023)

Tumor Microenvironment in Breast Cancer—Updates on Therapeutic Implications and Pathologic Assessment
por: Li, Joshua J., et al.
Publicado: (2021)

Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis
por: Wang, Yuefeng, et al.
Publicado: (2017)

Comprehensive Characterization of Pyroptosis Patterns with Implications in Prognosis and Immunotherapy in Low-Grade Gliomas
por: Zhou, Zijian, et al.
Publicado: (2022)

HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
por: Agostinetto, Elisa, et al.
Publicado: (2021)

Combining Analysis of Tumor-infiltrating Lymphocytes (TIL) and PD-L1 Refined the Prognostication of Breast Cancer Subtypes
por: Ni, Yunbi, et al.
Publicado: (2022)

Clinicopathological features and prognosis of patients with HER2-low breast cancer
por: Yang, Xin, et al.
Publicado: (2023)

HER2-LOW BREAST CANCER BRAIN METASTASES: INCIDENCE AND TREATMENT IMPLICATIONS
por: Chehade, Rania, et al.
Publicado: (2023)

The significance of highlighting the oestrogen receptor low category in breast cancer
por: Poon, Ivan K., et al.
Publicado: (2020)

Towards comprehensive characterization of HER2 overexpression
por: Berezov, Alan, et al.
Publicado: (2006)

Is BECN1 a Target Gene of Chromosome 17q21 Alteration in Breast Cancer?
por: Tsang, Julia Y.S., et al.
Publicado: (2015)

Association of clinicopathological features and prognosis of TERT alterations in phyllodes tumor of breast
por: Tsang, Julia Y. S., et al.
Publicado: (2018)

Comprehensive characterization of TNFSF14/LIGHT with implications in prognosis and immunotherapy of human gliomas
por: Han, Mingzhi, et al.
Publicado: (2022)

Comprehensive Characterization of a Novel E3-Related Gene Signature With Implications in Prognosis and Immunotherapy of Low-Grade Gliomas
por: Tan, Shichuan, et al.
Publicado: (2022)

Clinical characteristics, tumor‐infiltrating lymphocytes, and prognosis in HER2‐low breast cancer: A comparison study with HER2‐zero and HER2‐positive disease
por: Lu, Yujie, et al.
Publicado: (2023)

Can HER2 1+ Breast Cancer Be Considered as HER2-Low Tumor? A Comparison of Clinicopathological Features, Quantitative HER2 mRNA Levels, and Prognosis among HER2-Negative Breast Cancer
por: Shu, Lan, et al.
Publicado: (2022)

Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer
por: Gaibar, Maria, et al.
Publicado: (2020)

AJCC 8th edition prognostic staging provides no better discriminatory ability in prognosis than anatomical staging in triple negative breast cancer
por: He, Jiehua, et al.
Publicado: (2020)

HER-2 ultra-low breast cancer: exploring the clinicopathological features and prognosis in a retrospective study
por: Shi, Jiajie, et al.
Publicado: (2023)

Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer
por: Dai, Lei-Jie, et al.
Publicado: (2023)

Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
por: Tsang, R Y, et al.
Publicado: (2012)

HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients
por: Qin, Tao, et al.
Publicado: (2013)

FGFR1 and HER1 or HER2 co-amplification in breast cancer indicate poor prognosis
por: Chen, Shinan, et al.
Publicado: (2018)

Improving HER2 testing reproducibility in HER2-low breast cancer
por: Sajjadi, Elham, et al.
Publicado: (2022)

HER2/positive and HER2/low in inflammatory breast cancer recurrence
por: Movchan, Oleksii Volodimirovich, et al.
Publicado: (2022)

Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
por: Chen, Zhaoxu, et al.
Publicado: (2023)

Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature
por: Knauer, M, et al.
Publicado: (2010)

Clinicopathological Characteristics and Prognosis of HER2-Low Early-Stage Breast Cancer: A Single-Institution Experience
por: Xu, Hangcheng, et al.
Publicado: (2022)

The association between HER2-low expression and prognosis of breast cancer: a systematic review and meta-analysis
por: Tang, Yuyao, et al.
Publicado: (2023)

Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer
por: Sanomachi, Tomomi, et al.
Publicado: (2023)

Comparisons of clinical characteristics, prognosis, epidemiological factors, and genetic susceptibility between HER2‐low and HER2‐zero breast cancer among Chinese females
por: Zheng, Lu, et al.
Publicado: (2023)

The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment
por: Marchiò, Caterina, et al.
Publicado: (2018)

Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy
por: Pöschke, Patrik, et al.
Publicado: (2023)

Bioinformatics combined with clinical data to analyze clinical characteristics and prognosis in patients with HER2 low expression breast cancer
por: Chen, Yongcheng, et al.
Publicado: (2023)

A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies
por: Muraro, Elena, et al.
Publicado: (2011)

The Exciting New Field of HER2-Low Breast Cancer Treatment
por: Eiger, Daniel, et al.
Publicado: (2021)

Comprehensive Characterization of Immune Landscape Based on Epithelial-Mesenchymal Transition Signature in OSCC: Implication for Prognosis and Immunotherapy
por: Zhang, Si-yuan, et al.
Publicado: (2021)

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
por: Collins, Denis M., et al.
Publicado: (2019)

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
por: Kurozumi, Sasagu, et al.
Publicado: (2016)

Clinical implication of genetic composition and molecular mechanism on treatment strategies of HER2-positive breast cancers
por: Chow, Christopher Y.C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_skvena4fti4tnt0umbsfvka8so